Monthly Archives: November 2018
Françoise Baylis responds to the recently announced birth of the world’s first genome edited babies and raises concerns about the scientific practice and ethical accountability.
Deborah Gleeson and Ronald Labonté object to lengthening market exclusivity for biologic medicines in the United States-Mexico-Canada Agreement.
Jason Scott Robert suggests that the creation of part-human animals in stem cell biology may generate scientific confusion.
Yeyang Su invites Impact Ethics readers to mark their calendars for the second International Summit on Human Genome Editing.